This technical sheet follows the great interest raised by the new study published by Servy et al. on 33 couples with recurrent miscarriages where most of these women previously treated unsuccessfully with high doses of folic acid (5 mg/day) – after a treatment with Quatrefolic® supplements – finally had a pregnancy, increasing the overall ongoing pregnancy rate of +86.7%.
The leaflet also describes both the role of the methylenetetrahydrofolate reductase (MTHFR) polymorphism and of the homocysteine in fertility. Indeed, maternal folate and homocysteine status emerge as critical factors in the early stages of human reproduction.
Further evidence that choosing the right folate, such as Quatrefolic®, can definitely make a difference: Quatrefolic® provides the right folate dosage, it does not require metabolism of the MTHFR enzyme, it is ready to enter human metabolism and, if necessary, normalizes homocysteine plasma levels. |
Quatrefolic® demonstrates to be effective in fertility of both women and men (with MTHFR polymorphism), because it is the active folate form immediately bioavailable without metabolization.